Paper3122880
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ and 6 others. Br Med J (Clin Res Ed), 1987. Cited by 192 papers, by iCite.
Cite this record
ConductScience Library. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Papers, record 3122880. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3122880
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Iron | Major topic |
| Iron Chelating Agents | Major topic |
| Pyridones | Major topic |
| Thalassemia | Major topic |
| Administration, Oral | |
| Adolescent | |
| Adult | |
| Aged | |
| Ascorbic Acid | |
| Clinical Trials as Topic | |
| Deferiprone | |
| Deferoxamine | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Neural Tube Defects |
Source PubMed
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3954731 | Iron mobilization from ferritin using alpha-oxohydroxy heteroaromatic chelators. | Biochem J | 1986 | https://conductscience.org/library/papers/3954731 | PubMed |
| 2 | 3964556 | Orally active alpha-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbits. | Br J Haematol | 1986 | https://conductscience.org/library/papers/3964556 | PubMed |
| 3 | 3708002 | Iron mobilisation from lactoferrin by chelators at physiological pH. | Biochim Biophys Acta | 1986 | https://conductscience.org/library/papers/3708002 | PubMed |
| 4 | 3738427 | Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). | Scand J Haematol | 1986 | https://conductscience.org/library/papers/3738427 | PubMed |
| 5 | 3764334 | Dose response studies using desferrioxamine and orally active chelators in a mouse model. | Scand J Haematol | 1986 | https://conductscience.org/library/papers/3764334 | PubMed |
| 6 | 3566714 | Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators. | Biochem J | 1987 | https://conductscience.org/library/papers/3566714 | PubMed |
| 7 | 2884415 | 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. | Lancet | 1987 | https://conductscience.org/library/papers/2884415 | PubMed |
| 8 | 3435580 | New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones. | Arzneimittelforschung | 1987 | https://conductscience.org/library/papers/3435580 | PubMed |
| 9 | 63749 | Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload. | Lancet | 1976 | https://conductscience.org/library/papers/63749 | PubMed |
| 10 | 882111 | Continuous subcutaneous administration of deferoxamine in patients with iron overload. | N Engl J Med | 1977 | https://conductscience.org/library/papers/882111 | PubMed |
| 11 | 108388 | Rhodotorulic acid--investigation of its potential as an iron-chelating drug. | J Pharmacol Exp Ther | 1979 | https://conductscience.org/library/papers/108388 | PubMed |
| 12 | 497121 | Effective iron chelation following oral administration of an isoniazid-pyridoxal hydrazone. | Br J Haematol | 1979 | https://conductscience.org/library/papers/497121 | PubMed |
| 13 | 6106796 | Iron chelation with oral desferrioxamine. | Lancet | 1980 | https://conductscience.org/library/papers/6106796 | PubMed |
| 14 | 7093519 | Ferrioxamine excretion in iron-loaded man. | Blood | 1982 | https://conductscience.org/library/papers/7093519 | PubMed |
| 15 | 6135933 | Desferrioxamine suppositories. | Lancet | 1983 | https://conductscience.org/library/papers/6135933 | PubMed |
| 16 | 6227988 | [Iron chelation. Biological significance and medical application]. | Schweiz Med Wochenschr | 1983 | https://conductscience.org/library/papers/6227988 | PubMed |
| 17 | 6699459 | Phenolic ethylenediamine derivatives: a study of orally effective iron chelators. | J Lab Clin Med | 1984 | https://conductscience.org/library/papers/6699459 | PubMed |
| 18 | 2858689 | New orally active iron chelators. | Lancet | 1985 | https://conductscience.org/library/papers/2858689 | PubMed |
| 19 | 3942757 | The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators. | Biochim Biophys Acta | 1986 | https://conductscience.org/library/papers/3942757 | PubMed |
| 20 | 3485251 | Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. | N Engl J Med | 1986 | https://conductscience.org/library/papers/3485251 | PubMed |
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 192 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42797332 | Insights into the Complexities of Pharmacotherapy Parameters in Artificial Intelligence Models for Drug Selection, Precision Personalised Medicine and Optimal Therapeutic Outcomes. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42797332 | PubMed |
| 41156522 | Development of Iron-Chelating/Antioxidant Nutraceuticals and Natural Products as Pharmaceuticals for Clinical Use in Diseases with Free Radical Pathologies. | Nutrients | 2025 | https://conductscience.org/library/papers/41156522 | PubMed |
| 38791185 | The Puzzle of Aspirin and Iron Deficiency: The Vital Missing Link of the Iron-Chelating Metabolites. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38791185 | PubMed |
| 38515856 | Article review: Brazilin as potential anticancer agent. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38515856 | PubMed |
| 38069073 | Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38069073 | PubMed |
| 37513928 | The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/37513928 | PubMed |
| 36902402 | Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36902402 | PubMed |
| 36785546 | Serum Ferritin Levels and Other Associated Parameters with Diabetes Mellitus in Adult Patients Suffering from Beta Thalassemia Major. | J Blood Med | 2023 | https://conductscience.org/library/papers/36785546 | PubMed |
| 35743183 | Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35743183 | PubMed |
| 35163169 | Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163169 | PubMed |
| 33805195 | Is Chelation Therapy a Potential Treatment for Parkinson's Disease? | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33805195 | PubMed |
| 32751493 | Trying to Solve the Puzzle of the Interaction of Ascorbic Acid and Iron: Redox, Chelation and Therapeutic Implications. | Medicines (Basel) | 2020 | https://conductscience.org/library/papers/32751493 | PubMed |
| 32545424 | Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases. | Cells | 2020 | https://conductscience.org/library/papers/32545424 | PubMed |
| 31934321 | The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia. | Mediterr J Hematol Infect Dis | 2020 | https://conductscience.org/library/papers/31934321 | PubMed |
| 31533229 | The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain. | Pharmaceuticals (Basel) | 2019 | https://conductscience.org/library/papers/31533229 | PubMed |
| 28809446 | Deferasirox for managing iron overload in people with thalassaemia. | Cochrane Database Syst Rev | 2017 | https://conductscience.org/library/papers/28809446 | PubMed |
| 27276421 | Effects of renal impairment on the pharmacokinetics of orally administered deferiprone. | Br J Clin Pharmacol | 2016 | https://conductscience.org/library/papers/27276421 | PubMed |
| 27019793 | New developments and controversies in iron metabolism and iron chelation therapy. | World J Methodol | 2016 | https://conductscience.org/library/papers/27019793 | PubMed |
| 26056604 | Polymeric nanocarriers for the treatment of systemic iron overload. | Mol Cell Ther | 2015 | https://conductscience.org/library/papers/26056604 | PubMed |
| 25541601 | Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. | World J Methodol | 2014 | https://conductscience.org/library/papers/25541601 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3122880
GET https://conductscience.org/api/papers/v1/3122880/cited_by?page=2